fda and compounded tirzepatide Republican Administration Maintains Exclusivity Stance in GLP-1 (Tirzepatide) Compounding Dispute Compounded Semaglutide & Tirzepatide 2025:

Semaglutide, marketed as Ozempic and Wegovy, is an FDA-approved medication primarily used for type 2 diabetes management and chronic weight management

Following the December 2025 approval of 25-mg oral semaglutide (Wegovy

Lets take the first step together

WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity: to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight

But these findings are observational rather than from a randomized trial and thus need to be confirmed in other studies